Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neurometrix (NURO)
NASDAQ:NURO
Holding NURO?
Track your performance easily
Earnings Data
Report Date
Jan 23, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
―Last Year’s EPS
―Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 17, 2018
|% Change Since: 6.30%
|Next Earnings Date:Jul 19, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with strong growth in the Quell product line and effective cost management. However, these positives were offset by a significant revenue decline and ongoing challenges in the DPNCheck product line. The strategic review has yet to produce favorable outcomes, adding to the uncertainty.Company Guidance
During the NeuroMetrix Q2 2024 earnings call, Thomas Higgins, the CFO, highlighted several key financial metrics and business strategies. The company's revenue for the quarter was $769,000, down from $1.656 million in Q2 2023, primarily due to a decline in the DPNCheck product line, which was impacted by CMS rule changes. Despite this, Quell product revenue grew 47% year-over-year to $192,000. The company maintained a gross profit of $492,000, with a gross margin rate of 64%. Operating expenses were reduced by 15% to $2.3 million, following a Q1 reduction in force that lowered personnel costs. The net loss for the quarter was $1.488 million, marginally better than the $1.5 million loss in the prior year. NeuroMetrix ended the quarter with $16.4 million in liquid assets and a working capital of $16.9 million, aiming to decrease their $1.4 million quarterly cash usage further. The company is exploring potential new markets for DPNCheck and plans to expand its Quell business, including a possible De Novo submission for a new CIPN indication by the fourth quarter.Quell Revenue Growth
Quell revenue in Q2 was $192,000, representing a year-on-year gain of 47%. This indicates strong growth potential for the product.
Reduction in Operating Expenses
Operating expenses in Q2 were $2.3 million, down 15% from the prior year, due to a reduction in force and other cost-saving measures.
Quell Fibromyalgia Expansion
The Quell fibromyalgia product showed promising uptake in the Veterans Administration health system, presenting a new growth opportunity.
Quell Starter Kits and Refills Growth
Sales of Quell starter kits grew by 165% year-over-year, and there was a 13% growth in 1-month refills of Quell electrodes.
Strong Gross Margin
The company maintained a gross margin rate of 64%, with individual product gross margins stable for DPNCheck at 80% and improving for Quell.
---
NURO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NURO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $3.81 | $3.55 | -6.82% |
| Aug 06, 2024 | $3.54 | $3.16 | -10.73% |
| May 15, 2024 | $4.19 | $4.10 | -2.15% |
| Feb 22, 2024 | $3.17 | $2.94 | -7.26% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Neurometrix (NURO) report earnings?
Neurometrix (NURO) is schdueled to report earning on Jan 23, 2025, TBA Not Confirmed.
What is Neurometrix (NURO) earnings time?
Neurometrix (NURO) earnings time is at Jan 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NURO EPS forecast?
Currently, no data Available
---